Phanes Therapeutics Announces First Patient Dosed in Phase I Study of PT886 for Advanced Gastric, Gastroesophageal Junction and Pancreatic Adenocarcinomas

Phanes Therapeutics, Inc. announced that the first patient has been dosed in the phase I clinical study (NCT05482893) of PT886, a first-in-class native IgG-like bispecific antibody targeting claudin 18.2 and CD47 for the treatment of gastric, gastroesophageal junction, and PDACs.